Crossmark

Reply to ‘Time for a change and to adopt a novel molecular genomic approach in NETs’

Crossref DOI link: https://doi.org/10.1038/s41571-019-0186-4

Published Online: 2019-02-26

Published Print: 2019-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Rindi, Guido http://orcid.org/0000-0003-2996-4404
Wiedenmann, Bertram
License Information

Text and Data Mining valid from 2019-02-26
More Information

Article History

First Online: 26 February 2019

Competing interests

: G.R. has received honoraria from Ipsen and Novartis for his role in their speaker’s bureau. B.W. declares no competing interests.